Drugs / GI-102
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05824975 | May 2023 → Nov 2025 overdue | Her2-receptor negative breast cancer, colorectal cancer, cutaneous melanoma, hepatocellular carcinoma +3 | GI Innovation, Inc. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07301268 | Apr 2026 → Apr 2029 expected | IDH-wildtype glioblastoma, astrocytoma, IDH-mutant, grade 4, gliosarcoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT07363057 | Jan → May 2026 overdue | — | GI Innovation, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GI-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05824975 ↗ |
| Action | Inhibit | “The CD80 portion is responsible for targeting tumor/immune cells while blocking CTLA-4 expressed on the Treg cells.” NCT05824975 ↗ |
| Modality | Protein / enzyme biologic | “GI-102 is a novel bi-specific Fc fusion protein” NCT05824975 ↗ |
| Route | Intravenous | “GI-102 intravenous (IV)” NCT05824975 ↗ |